Admin_Adham
Race Does Not Impact Dupilumab Response in Kids With AD
TOPLINE:
Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic dermatitis.
METHODOLOGY:
- Dupilumab, approved for treating AD in children aged 6 months and older, is effective for treating pediatric AD, but data comparing improvement across racial or ethnic subgroups are limited.
- Researchers reviewed medical records of 236 children with AD on dupilumab treated at a single medical center between January 2017 and October 2024.
- They compared physician assessments of children of different ethnicities who were treated with dupilumab.
TAKEAWAY:
- No significant differences in dupilumab response appeared across ethnic subgroups, which included White Hispanic, non-White Hispanic, White non-Hispanic, Black non-Hispanic, and Asian non-Hispanic groups (P = .07).
- Comparison of White and non-White children also showed no significant difference in physician assessment of dupilumab response (P = .07).
- The similarity in dupilumab response can inform clinical decision-making for pediatric AD patients with varying phenotypes.
IN PRACTICE:
“The results of this study suggest that race and ethnicity do not impact response to dupilumab for pediatric patients with AD,” the authors concluded.
SOURCE:
The study was presented at the annual meeting of the American Contact Dermatitis Society. The lead author was Jared M. Boetes, MS, a medical student at the University of Pennsylvania, Philadelphia.
LIMITATIONS:
The variability in provider assessment of AD was a potential limiting factor in the study, as was the reliance on self-reported race and ethnicity.
DISCLOSURES:
The study received no outside funding. The researchers had no financial conflicts to disclose.
